Target Countries:

Central & South America, Southeast Asia

Highlights

1. Intravenous injection, anti infection & immunomodulatory;

2. Prove to be effective in the COVID therapy;

3. Derived from human plasma with few adverse effects;

4. Complete IgG subclass, conforming to normal human plasma ratio;

5. Wider spectrum of antibodies.

Indications

1. Primary immunoglobulin deficiency diseases, such as X-linked hypoimmunoglobinemia, common variable immunodeficiency disease (CVID), IgG subclass deficiency, etc. 

2. Secondary immunoglobulin deficiency diseases, such as severe infections, neonatal sepsis, etc.

Autoimmune diseases (AID), such as primary thrombocytopenic purpura, Kawasaki disease (KD), etc.

Dosage Form 

It is a clear, colorless or light yellow liquid. Opalescence may occur but without turbidity.

Specifications 

10g(5% 200ml), 5g(5% 100ml), 2.5g(5% 50ml), 1.25g(5% 25ml), 1g(5% 20ml)

Shelf life 

24 months

Specific Requirements

Deal in the related industry;
Familiar with local regulation for drug entry;
Familiar with local sales channel and market;
Active and confident in promoting the product.